Open Access Articles- Top Results for Brofaromine


Systematic (IUPAC) name
Clinical data
  • (Prescription only)
Pharmacokinetic data
Protein binding 98%
Half-life 9-14 hours
63638-91-5 7pxY
PubChem CID 44571
ChemSpider 40549 7pxY
UNII 6WV4B8Q07H 7pxY
KEGG D02560 7pxY
ChEMBL CHEMBL160347 7pxY
Chemical data
Formula C14H16BrNO2
310.186 g/mol
 14pxY (what is this?)  (verify)

Brofaromine (Consonar) is a reversible inhibitor of monoamine oxidase A discovered by Ciba-Geigy.[1] The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.[2]

Brofaromine also has serotonin reuptake inhibitory properties and its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs.


Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.


  1. ^ US Patent 4210655
  2. ^ Lotufo-Neto F, Trivedi M, Thase ME (1999). "Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression". Neuropsychopharmacology 20 (3): 226–47. PMID 10063483. doi:10.1016/S0893-133X(98)00075-X.  Free full text

Lua error in package.lua at line 80: module 'Module:Buffer' not found.